Dr. Park on the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL – OncLive

Jae Park, MD, discussesthebenefits of off-the-shelf CAR T-cell therapy inacute lymphoblasticleukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discussesthebenefits of off-the-shelf CAR T-cell therapy inacute lymphoblasticleukemia (ALL).

Patients with low lymphocyte counts afterchemotherapy or allogeneic stem cell transplantationcould benefit from off-the-shelf CAR T-cell products ascollectingT cellscan be challenging, says Park.

Moreover,patients may experience disease progression during the 3 to 4-week period of T-cell generationthat may be mitigated by an off-the-shelf option, concludes Park.

See the original post here:

Dr. Park on the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL - OncLive